SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January, 2024
Commission
File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7)
only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
Date: January 3, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
|
K Randhir Singh |
|
|
Title: |
|
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s
Laboratories Ltd.
8-2-337,
Road No. 3, Banjara Hills,
Hyderabad
- 500 034, Telangana,
India.
CIN :
L85195TG1984PLC004507
Tel :
+91 40 4900 2900
Fax :
+91 40 4900 2999
Email
: mail@drreddys.com
www.drreddys.com |
January 3, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock
Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
Subject: Press Release
Please find enclosed a Press Release on “Dr. Reddy's announces the acquisition of MenoLabs®, a leading women’s
health and dietary supplements portfolio of brands”.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Encl: As above
Press
Release |
|
DR. REDDY’S LABORATORIES LTD.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India. |
CONTACT |
Investor relations |
Media relationS |
RICHA PERIWAL
richaperiwal@drreddys.com |
USHA IYER
ushaiyer@drreddys.com |
Dr.
Reddy’s announces the acquisition of MenoLabs®, a leading
women’s health and dietary supplements portfolio of brands
Hyderabad, India, and Princeton,
NJ, U.S.; January 3, 2024 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with
its subsidiaries together referred to as “Dr. Reddy’s”), today announced that it has acquired MenoLabs® business,
a leading women’s health and dietary supplement branded portfolio from Amyris, Inc. (“Amyris”) in Amyris’ Chapter
11 sales process.
Dr. Reddy’s acquired the entire
MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause
and menopause. Brands include MenoFit™ and MenoGlow™ probiotics, Happy Fiber™ and Well Rested™ dietary supplements,
Athena’s Shield™ menopause support supplement, and Goodness Glow™ and Keep Glowing Gorgeous™ supplements for
healthy aging support. The deal also includes the MenoLife® health tracker app which supports the product line and provides community,
education, and information to consumers regarding menopause. MenoLabs portfolio of products is sold in the United States, primarily through
the brand’s own [https://menolabs.com] and other e-commerce marketplaces including Amazon and Walmart.
“The MenoLabs acquisition will
serve as a catalyst to accelerate growth in this space and build upon our aspiration to lead in the fast-growing women’s nutritional
and wellness markets,” says Marc Kikuchi, Chief Executive Officer for Dr. Reddy’s in North America. “The acquisition
complements Dr. Reddy’s U.S. self-care and wellness business portfolio of brands and addresses unmet needs of consumers for science-based,
research-driven products that provide relief from the symptoms of menopause. For these and many other reasons, I believe we are well-positioned
to successfully integrate and grow the business.”
RDY-1123-OTC
About Dr. Reddy’s: Dr.
Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered
in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our
purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded
generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a
company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of
the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG
goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more
information, log on to: www.drreddys.com.
Disclaimer: This press release may
include statements of future expectations and other forward-looking statements that are based on the management’s current views
and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context,
the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”,
“believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to
without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates,
interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii)
changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks
and/or governments, (v) the
impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility
of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of
natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties
identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors”
and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2023. The company assumes
no obligation to update any information contained herein.
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024